Silexion Therapeutics Corp
SLXNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002022416
No open-market purchases or sales by Silexion Therapeutics Corp insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $70.3K in total; no superinvestor holds it.
Other share classesSLXN
13F holders, Q3 2025
Institutional positions in Silexion Therapeutics Corp as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +1 vs. Q2 2025
- Shares held
- 2.56M
- +120.5K (+4.9%) vs. Q2 2025
- Total value
- $89.8K
- −$8.90K (−9.0%) vs. Q2 2025
- New holders
- 2
- 2 more added
- Sold out
- 1
- 0 more reduced
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SLXNW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $70.3K |
| Q1 2026 | 19 | $47.7K |
| Q4 2025 | 22 | $61.8K |
| Q3 2025 | 22 | $89.8K |
| Q2 2025 | 22 | $107.6K |
| Q1 2025 | 25 | $199.1K |
| Q4 2024 | 26 | $91.7K |
| Q3 2024 | 32 | $106.1K |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Silexion Therapeutics Corp; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 743,475 | $26.2K | 0.00% | 00.0% | Unchanged |
| Linden Advisors LP | 337,500 | $12.2K | 0.00% | 00.0% | Unchanged |
| Aristeia Capital LLC | 236,546 | $8.34K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 220,053 | $7.75K | 0.00% | +69,071+45.7% | Added |
| Clear Street Group Inc. | 219,565 | $7.73K | 0.00% | +219,565 | New |
| Security Benefit Life Insurance Co | 150,000 | $5.28K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 116,639 | $4.11K | 0.00% | +3,071+2.7% | Added |
| Kepos Capital LP | 100,000 | $4.00K | 0.02% | 00.0% | Unchanged |
| Jane Street Group, LLC | 74,910 | $2.64K | 0.00% | 00.0% | Unchanged |
| Context Capital Management, LLC | 51,183 | $1.80K | 0.00% | 00.0% | Unchanged |
| Tenor Capital Management Co., L.P. | 50,000 | $1.76K | 0.00% | 00.0% | Unchanged |
| Gabelli & Co Investment Advisers, Inc. | 38,150 | $1.34K | 0.00% | 00.0% | Unchanged |
| DuPont Capital Management Corp | 32,500 | $1.14K | 0.00% | 00.0% | Unchanged |
| Neuberger Berman Group LLC | 31,552 | $1.11K | 0.00% | 00.0% | Unchanged |
| Gabelli Funds LLC | 30,496 | $1.07K | 0.00% | 00.0% | Unchanged |
| Picton Mahoney Asset Management | 57,175 | $1.00K | 0.00% | 00.0% | Unchanged |
| Mint Tower Capital Management B.V. | 25,000 | $1.00K | 0.00% | 00.0% | Unchanged |
| Stifel Financial Corp | 16,000 | $563 | 0.00% | 00.0% | Unchanged |
| Saba Capital Management, L.P. | 11,937 | $421 | 0.00% | 00.0% | Unchanged |
| Cobblestone Capital Advisors LLC | 10,000 | $352 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 100 | $4 | 0.00% | 00.0% | Unchanged |
| Oasis Management Co Ltd. | 11,111 | – | – | +11,111 | New |
| Hartree Partners, LP | 0 | $0 | 0.00% | −182,355−100.0% | Sold out |
| Clear Street LLC | – | – | – | – | Not filed |